Coccidioidomycosis

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Retrieved on: 
Monday, February 26, 2024

BEDMINSTER, N.J., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today provided an update from its ongoing Compassionate/Expanded Use Access Program (the “Program”) with MAT2203, the Company’s proprietary, LNC-delivered oral formulation of the broad-spectrum antifungal drug amphotericin B.

Key Points: 
  • Treatment with MAT2203 was well tolerated and led to favorable clinical and radiological response and we did not observe any renal toxicity.
  • 5 additional patients have shown objective improvement in clinical markers and are continuing treatment with MAT2203 as planned.
  • 2 patients transitioned to palliative care shortly after starting therapy with MAT2203 because of unanticipated progression of their malignant disease.
  • “We continue to be excited about the ongoing, consistent positive clinical impact of MAT2203, seen in these extremely ill patients,” said Theresa Matkovits, PhD, Chief Development Officer at Matinas .

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Posaconazole Accord, posaconazole, Date of authorisation: 25/07/2019, Revision: 8, Status: Authorised

NFL Star Rob Gronkowski and Anivive Lifesciences Join Congressional Leaders on Capitol Hill to Combat the Rising Threat of Valley Fever

Retrieved on: 
Tuesday, December 19, 2023

WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever. Intensified by climate change, this fungal infection is not only a burgeoning public health concern in the American Southwest but also a significant economic burden, costing the U.S. healthcare system an estimated $3.9 billion annually.

Key Points: 
  • - Capitol Hill puts Valley fever in the spotlight just in time as Anivive's canine vaccine is under regulatory review.
  • - Congress introduced 4 bills that aim to fast-track the FDA review of Valley fever solutions and authorize $500 million to support fungal disease initiatives.
  • WASHINGTON, Dec. 19, 2023 /PRNewswire/ -- On Capitol Hill last Tuesday, NFL Icon and 4-time Super Bowl Champion Rob Gronkowski and Senators Mark Kelly, Kyrsten Sinema, Markwayne Mullin, and Representative David Schweikert led an event focused squarely on the rising challenge of Valley Fever.
  • Valley Fever, a serious fungal infection caused by the soil-dwelling Coccidioides, results in tens of thousands of human cases each year.

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

Retrieved on: 
Saturday, October 21, 2023

These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.

Key Points: 
  • These findings were submitted as a late breaking abstract and exceptionally accepted for an oral presentation during the 11th Congress on Trends in Medical Mycology (TIMM) 2023 held in Athens, Greece, from 20-23 October 2023.
  • F2G and Shionogi & Co., Ltd. are collaborating to develop and commercialise olorofim, bringing the novel antifungal therapy to patients with invasive fungal infections.
  • F2G has commercial responsibility for olorofim in North America, and Shionogi has commercial responsibility for olorofim in Europe and Asia Pacific.
  • F2G and Shionogi are currently enrolling patients with invasive aspergillosis in a global Phase 3 study (OASIS) to compare treatment with olorofim versus AmBisome® followed by standard of care ( NCT05101187 ).

Petco Love Joins Forces With Anivive Lifesciences and Rob Gronkowski to Champion The Fight Against Valley Fever

Retrieved on: 
Wednesday, August 30, 2023

LONG BEACH, Calif., Aug. 30, 2023 /PRNewswire/ -- Today, national nonprofit Petco Love, Anivive Lifesciences, and former NFL superstar Rob Gronkowski announced a groundbreaking partnership focused on bringing awareness to the growing threat of Valley Fever.

Key Points: 
  • LONG BEACH, Calif., Aug. 30, 2023 /PRNewswire/ -- Today, national nonprofit Petco Love, Anivive Lifesciences, and former NFL superstar Rob Gronkowski announced a groundbreaking partnership focused on bringing awareness to the growing threat of Valley Fever.
  • Saving pets impacted by valley fever involves a combination of awareness, environmental management, and proper care.
  • Raising Awareness: Valley Fever is more common in arid and desert areas, such as the southwestern United States.
  • Uniting in this vital cause, Petco Love, Anivive Lifesciences, and Rob Gronkowski call upon communities, veterinarians, and pet enthusiasts to mobilize against Valley Fever, envisioning a future of healthier and happier lives for pets and the people who love them.

GRONK COMMITS $1 MILLION TO ANIVIVE FOR VALLEY FEVER VACCINES

Retrieved on: 
Thursday, March 2, 2023

As the proud pet parent to his French Bulldog Ralphie, Gronk is committed to pets and their owners to have access to affordable and innovative care.

Key Points: 
  • As the proud pet parent to his French Bulldog Ralphie, Gronk is committed to pets and their owners to have access to affordable and innovative care.
  • The application of this vaccine could help more than 30 million dogs who are at risk for Valley Fever.
  • Gronk's donation will allow Anivive's Valley Fever vaccine to be distributed to low-income families and animals within shelters across Arizona.
  • Valley Fever is most commonly found in Arizona and Anivive is actively looking for partners to facilitate the donations within the State.

Matinas BioPharma Provides Business Update and 2023 Strategic Outlook

Retrieved on: 
Monday, January 30, 2023

ET

Key Points: 
  • ET
    BEDMINSTER, N.J., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB, Matinas), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, today is providing a business update on its ongoing programs and discussing its strategic outlook for 2023.
  • Our ongoing collaborations with BioNTech and, recently, National Resilience, have aligned Matinas with two of the world’s leading companies in the gene therapy space.
  • The Company will host a live conference call and webcast to discuss this corporate update and 2023 business outlook today, Monday, January 30 at 4:30 p.m.
  • The live webcast will be accessible on the Investors section of Matinas BioPharma’s website, www.matinasbiopharma.com , and archived for 90 days.

Anivive Sponsors National Academy of Sciences Valley Fever Workshop

Retrieved on: 
Wednesday, November 16, 2022

LONG BEACH, Calif., Nov. 16, 2022 /PRNewswire/ -- Anivive Lifesciences, a technology-driven pet pharmaceutical company currently in late-stage development on the commercialization of a Canine Valley Fever Vaccine, announces they will be co-sponsoring The National Academies of Sciences, Engineering, and Medicine (NASEM) - Impact and Control of Valley Fever workshop.

Key Points: 
  • LONG BEACH, Calif., Nov. 16, 2022 /PRNewswire/ -- Anivive Lifesciences, a technology-driven pet pharmaceutical company currently in late-stage development on the commercialization of a Canine Valley Fever Vaccine, announces they will be co-sponsoring The National Academies of Sciences, Engineering, and Medicine (NASEM) - Impact and Control of Valley Fever workshop.
  • The workshop will take place on November 17th and 18th at the Arnold and Mabel Beckman Center in Irvine, CA.
  • It will feature speakers from around the world who are involved in research, development, and public health initiatives related to Valley Fever.
  • Economic valuation of coccidioidomycosis (valley fever) projections in the United States in response to climate change.

F2G Announces Data from Phase 2b Study at ID Week 2022 Showing Positive Therapeutic Response in Patients with Invasive Fungal Infections Treated with Olorofim

Retrieved on: 
Friday, October 21, 2022

Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.

Key Points: 
  • Approximately 75% of patients in this analysis had moderate to high levels of immunosuppression, with about half suffering from fungal infections due to Aspergillus.
  • Data came from 100 patients with proven invasive fungal infection or probable pulmonary invasive aspergillosis (IA).
  • Mortality remains unacceptably high in patients with severe and life-threatening fungal infections being treated with currently available therapies.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.

F2G to Present Interim Results from Phase 2B Open Label Study of Olorofim in Invasive Fungal Infections at IDWeek 2022

Retrieved on: 
Thursday, October 13, 2022

The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.

Key Points: 
  • The Company will also present posters on pharmacokinetic data from Phase 1 and Phase 2B studies of olorofim antifungal therapy.
  • Olorofim has received orphan drug status from the European Medicines Agency for the treatment of invasive aspergillosis and invasive scedosporiosis.
  • Olorofim has been granted Qualified Infectious Disease Product (QIDP) designation for invasive aspergillosis, invasive scedosporiosis, invasive lomentosporiosis, coccidioidomycosis, invasive disease due to Scopulariopsis species, and invasive fusariosis.
  • Invasive aspergillosis is a rare disease that can occur in over 10% of some high-risk immunosuppressed populations with mortality exceeding 80%.